Beta Bionics, Inc. (BBNX) EBITDA (2024 - 2026)

Beta Bionics (BBNX) has 3 years of EBITDA data on file, last reported at -$22.4 million in Q1 2026.

• Quarterly EBITDA rose 21.37% year-over-year to -$22.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$66.8 million (up 5.59% YoY) and the FY2025 annual result came in at -$72.9 million, down 32.89% from the prior year.
• EBITDA eased to -$22.4 million in Q1 2026 per BBNX's latest filing, from -$13.4 million in the prior quarter.
• The five-year high for EBITDA was -$9.7 million in Q3 2024, with the low at -$28.5 million in Q1 2025.
• Average EBITDA over 3 years is -$16.7 million, with a median of -$14.5 million recorded in 2024.
• The widest YoY moves for EBITDA: up 25.88% in 2025, down 126.38% in 2025.
• Beta Bionics' EBITDA stood at -$18.1 million in 2024, then rose by 25.88% to -$13.4 million in 2025, then plunged by 66.91% to -$22.4 million in 2026.
• Business Quant data shows BBNX's EBITDA at -$22.4 million in Q1 2026, -$13.4 million in Q4 2025, and -$14.0 million in Q3 2025.